初级保健中维持酒精戒断的治疗干预:系统综述与网络荟萃分析
该系统综述与网络荟萃分析纳入64项随机对照试验(43种干预),评估近期戒酒成功的酒精依赖患者在初级保健中维持戒断的干预效果。结果显示,与安慰剂相比,仅阿坎酸(acamprosate)与戒断概率增加相关(OR 1.86, 95%CI 1.49-2.33),且证据确定性中等;阿坎酸、纳曲酮及两药联合与全因脱落减少相关。其他干预因证据确定性低,效果不确定。
要点
- 阿坎酸是唯一在维持戒断和减少脱落上均有中等确定性证据的干预。
- 阿坎酸、纳曲酮及阿坎酸-纳曲酮联合均可减少全因脱落。
- 其他干预因证据确定性低,维持戒断和减少脱落的效果不确定。
核心结论
- 在初级保健可实施的干预中,仅阿坎酸有中等确定性证据支持其维持酒精戒断和减少脱落。
- 其他干预因证据确定性低,能否帮助维持戒断和减少脱落尚不确定。
- 需要更多高质量随机对照试验及联合干预策略的证据。
研究设计与样本
- 系统综述与网络荟萃分析,检索Medline、Embase、PsycINFO、Cochrane CENTRAL、ClinicalTrials.gov及WHO ICTRP。
- 纳入64项随机对照试验(43种干预),对象为标准化工具诊断的酒精依赖且4周内戒酒成功的患者。
- 结局为干预开始至少12周后的持续戒酒(有效性)和全因脱落(可接受性代理指标)。
主要发现
- 安慰剂组戒断概率中位数为25%。
- 与安慰剂相比,阿坎酸与戒断概率增加相关(OR 1.86, 95%CI 1.49-2.33),对应绝对概率38%。
- 在62项报告全因脱落的试验中,与安慰剂(概率50%)相比,阿坎酸(OR 0.73, 95%CI 0.62-0.86;42%)、纳曲酮(OR 0.70, 95%CI 0.50-0.98;41%)及阿坎酸-纳曲酮联合(OR 0.30, 95%CI 0.13-0.67;17%)与脱落减少相关。
- 阿坎酸是唯一在有效性和可接受性上均有中等确定性证据且持续至12个月的干预。
关键数值与推荐
- 阿坎酸对比安慰剂:戒断OR 1.86(95%CI 1.49-2.33),绝对概率38% vs 25%。
- 阿坎酸对比安慰剂:全因脱落OR 0.73(95%CI 0.62-0.86),概率42% vs 50%。
- 纳曲酮对比安慰剂:全因脱落OR 0.70(95%CI 0.50-0.98),概率41% vs 50%。
- 阿坎酸-纳曲酮联合对比安慰剂:全因脱落OR 0.30(95%CI 0.13-0.67),概率17% vs 50%。
临床怎么用
- 在初级保健中,对近期戒酒成功的酒精依赖患者,可优先考虑阿坎酸以维持戒断。
- 阿坎酸、纳曲酮或两药联合可用于减少治疗脱落。
- 其他干预措施因证据不确定性高,暂不推荐作为首选。
局限性
- 多数干预的证据确定性低,无法确定其维持戒断和减少脱落的效果。
- 需要更多高质量随机对照试验及联合干预策略的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the most effective interventions in recently detoxified, alcohol dependent patients for implementation in primary care. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Medline, Embase, PsycINFO, Cochrane CENTRAL, ClinicalTrials.gov, and the World Health Organization's International Clinical Trials Registry Platform. STUDY SELECTION: Randomised controlled trials comparing two or more interventions that could be used in primary care. The population was patients with alcohol dependency diagnosed by standardised clinical tools and who became detoxified within four weeks. DATA EXTRACTION: Outcomes of interest were continuous abstinence from alcohol (effectiveness) and all cause dropouts (as a proxy for acceptability) at least 12 weeks after start of intervention. RESULTS: 64 trials (43 interventions) were included. The median probability of abstinence across placebo arms was 25%. Compared with placebo, the only intervention associated with increased probability of abstinence and moderate certainty evidence was acamprosate (odds ratio 1.86, 95% confidence interval 1.49 to 2.33, corresponding to an absolute probability of 38%). Of the 62 included trials that reported all cause dropouts, interventions associated with a reduced number of dropouts compared with placebo (probability 50%) and moderate certainty of evidence were acamprosate (0.73, 0.62 to 0.86; 42%), naltrexone (0.70, 0.50 to 0.98; 41%), and acamprosate-naltrexone (0.30, 0.13 to 0.67; 17%). Acamprosate was the only intervention associated with moderate confidence in the evidence of effectiveness and acceptability up to 12 months. It is uncertain whether other interventions can help maintain abstinence and reduce dropouts because of low confidence in the evidence. CONCLUSIONS: Evidence is lacking for benefit from interventions that could be implemented in primary care settings for alcohol abstinence, other than for acamprosate. More evidence from high quality randomised controlled trials is needed, as are strategies using combined interventions (combinations of drug interventions or drug and psychosocial interventions) to improve treatment of alcohol dependency in primary care. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42016049779.
引用
- Cheng HY, McGuinness LA, Elbers RG, et al. Treatment interventions to maintain abstinence from alcohol in primary care: systematic review and network meta-analysis. BMJ. 2020. PMID: 33239318. doi:10.1136/bmj.m3934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。